American Society of Hirudotherapy

Microglia of medicinal leech (Hirudo medicinalis) express a specific activation marker homologous to vertebrate ionized calcium-binding adapter molecule 1 (Iba1/alias aif-1)

Research article published in Developmental neurobiology (2014)

Last Updated: November 1, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomics & ProteomicsDrago F et al. · Developmental neurobiology, 2014

Abstract

The Ionized calcium-Binding Adapter molecule 1 (Iba1), also known as Allograft Inflammatory Factor 1 (AIF-1), is a 17 kDa cytokine-inducible protein, produced by activated macrophages during chronic transplant rejection and inflammatory reactions in Vertebrates. In mammalian central nervous system (CNS), Iba1 is a sensitive marker associated with activated macrophages/microglia and is upregulated following neuronal death or brain lesions. The medicinal leech Hirudo medicinalis is able to regenerate its CNS after injury, leading to a complete functional repair. Similar to Vertebrates, leech neuroinflammatory processes are linked to microglia activation and recruitment at the lesion site. We identified a gene, named Hmiba1, coding a 17.8 kDa protein showing high similarity with Vertebrate AIF-1. The present work constitutes the first report on an Iba1 protein in the nervous system of an invertebrate. Immunochemistry and gene expression analyses showed that HmIba1, like its mammalian counterpart, is modulated in leech CNS by mechanical injury or chemical stimuli (ATP). We presently demonstrate that most of leech microglial cells migrating and accumulating at the lesion site specifically expressed the activation marker HmIba1. While the functional role of Iba1, whatever species, is still unclear in reactive microglia, this molecule appeared as a good selective marker of activated cells in leech and presents an interesting tool to investigate the functions of these cells during nerve repair events.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAdenosine TriphosphateAnimalsBlotting, WesternCalcium-Binding ProteinsDNA-Binding ProteinsGanglia, InvertebrateGene ExpressionHirudo medicinalisImmunohistochemistryMicrofilament ProteinsMicrogliaNeuroimmunomodulationSequence Homology

Summary

This study identifies HmIba1, a 17.8 kDa Hirudo medicinalis protein homologous to vertebrate AIF-1/Iba1, the first Iba1 reported in an invertebrate nervous system; it is modulated by injury or ATP and expressed by activated microglia accumulating at lesion sites.

Why This Matters for Hirudotherapy

This study identified and characterized HmIba1, a leech homolog of the vertebrate ionized calcium-binding adapter molecule 1 (Iba1/AIF-1), demonstrating that it serves as a specific marker for microglial cells that migrate and accumulate at lesion sites in the CNS of Hirudo medicinalis after mechanical or chemical injury. The work advances fundamental understanding of the medicinal leech's innate neuroimmune and regenerative biology, processes linked to the CNS repair capacity of this species. However, the study examines the leech's own nervous system and does not investigate leech salivary secretions, therapeutic bioactive compounds, or clinical outcomes of hirudotherapy. The authors note that the functional role of Iba1 remains unclear across species, and the findings primarily establish a research tool for future investigation.

Citation

Reference (Vancouver style)

Drago F, Sautière PE, Le Marrec-Croq F, Accorsi A, Van Camp C, Salzet M, et al. Microglia of medicinal leech (Hirudo medicinalis) express a specific activation marker homologous to vertebrate ionized calcium-binding adapter molecule 1 (Iba1/alias aif-1). Dev Neurobiol. 2014;74(10):987-1001. doi:10.1002/dneu.22179. PMID: 24723370

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.